GSK-backed ViiV says phase IIIb CROWN trial shows Cabenuva beats daily oral HIV therapy in viral suppression
GSK•ViiV said its phase IIIb CROWN trial found better viral suppression with Cabenuva than daily oral therapy in people with unsuppressed HIV at entry; use in people with detectable virus remains investigational.
